Magnetocardiography in the Accurate Identification of Myocardial Infarction
Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · May 31, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method called magnetocardiography (MCG) to help accurately identify heart attacks, also known as myocardial infarctions. MCG is a non-invasive test, meaning it doesn't require any surgery or injections, and it could potentially provide better detection of heart issues in patients experiencing chest pain. The researchers want to see how well this new method works compared to standard tests like electrocardiograms (ECGs) and blood tests that check for heart damage.
To participate in this study, you need to be between 18 and 79 years old. Healthy volunteers should not have any history of heart disease or related conditions, while patients with chest pain who are suspected of having heart problems may also join. Participants will undergo a series of tests, including MCG, ECGs, and other imaging methods, so they can help researchers understand how effective MCG is. If you're interested in joining, you would need to provide consent and meet certain health criteria, but those with specific health conditions or concerns may not be eligible. This trial is currently recruiting participants, and it's a great opportunity to contribute to important heart health research!
Gender
ALL
Eligibility criteria
- For healthy volunteers:
- Inclusion Criteria:
- • 1. Age 18-79 years old;
- • 2. No history of cardiovascular disease (coronary heart disease, structural heart disease, arrhythmia, heart failure, stroke, pulmonary embolism, aortic dissection, etc.), no cardiovascular risk factors (hypertension, diabetes, hyperlipidemia). For people over 65 years old, those with hypertension or hyperlipidemia, but with well-controlled blood pressure and lipid levels, taking no more than 2 drugs, and echocardiography showing no left ventricular hypertrophy, can be included;
- • 3. The electrocardiogram is normal, and the cardiac ultrasound is basically normal in the past 1 year (mild valvular regurgitation can be included).
- • 4. Sign the informed consent.
- Exclusion Criteria:
- • 1. Those who with acute or chronic respiratory diseases;
- • 2. Those who with obvious abnormality of liver or kidney function;
- • 3. Those who with endocrine diseases such as abnormal thyroid function;
- • 4. Those who with anemia or other blood diseases;
- • 5. Those who with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.);
- • 6. Those who are obese (BMI\>30kg/cm2) or underweight (BMI\<18kg/cm2);
- • 7. Those who with malignant tumors;
- • 8. Those who with infectious diseases or infectious diseases;
- • 9. Those who with trauma or physical disability;
- • 10. Those who with psychological or mental illness such as depression;
- • 11. Those who are professional athletes, pregnant or breastfeeding women, alcoholics;
- • 12. Those who are unable to perform magnetocardiography examination due to claustrophobia, etc., or those who fail to receive magnetocardiography examination;
- • 13. Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements.
- For chest pain patients who will receive ECG, biomarkers, or non-invasive imaging examination:
- Inclusion Criteria:
- • 1. Age 18-79 years old;
- • 2. Those with chest pain symptoms, diagnosed or highly suspected by the attending doctor or above as stable angina pectoris (SA), unstable angina pectoris (UA), non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI), and plan to receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography);
- • 3. Sign the informed consent.
- Exclusion Criteria:
- • 1. Patients with known structural heart disease such as cardiomyopathy and valvular disease;
- • 2. Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal;
- • 3. History of other cardiovascular diseases such as pulmonary embolism and aortic dissection;
- • 4. Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;
- • 5. Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
- • 6. Obese (BMI\>30kg/cm2) or underweight (BMI\<18kg/cm2);
- • 7. Patients with malignant tumors;
- • 8. Professional athletes, pregnant or breastfeeding women, alcoholics;
- • 9. Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;
- • 10. Patients with infectious diseases or infectious diseases;
- • 11. Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;
- • 12. Unable to or fail to cooperate with the corresponding research requirements.
About Qilu Hospital Of Shandong University
Qilu Hospital of Shandong University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Affiliated with Shandong University, the hospital integrates clinical practice with education and research, fostering an environment that promotes scientific discovery and the development of new therapies. With a commitment to high standards of clinical excellence and ethical research practices, Qilu Hospital plays a pivotal role in enhancing patient outcomes and contributing to the global medical community through a diverse range of clinical trials and studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Jinan, Shandong, China
Patients applied
Trial Officials
Yuguo Chen, Dr
Principal Investigator
Qilu Hospital of Shandong University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported